Friday, January 27, 2023

January 23, 2023 at 01:28PM ODACTRA

Product approval information for use in adults 18 through 65 years of age as immunotherapy for house dust mite- (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/yoxSsZi

No comments:

Post a Comment